AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1942508 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.1 mg.kg‐1 + 10 ml saline
Number of subjects: 21
Study 1942508 — intervention group
Group type: COMPARATOR
Intervention: Saline only (10 ml)
Number of subjects: 21
Study 6798624 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol with monetary and performance feedback reinforcement
Number of subjects: 0
Study 6798624 — intervention group
Group type: COMPARATOR
Intervention: Alcohol without reinforcement
Number of subjects: 0
Study 6798624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6798624 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol with withdrawal of reinforcement
Number of subjects: 0
Study 31157368 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention clinics
Number of subjects: 6836
Study 31157368 — intervention group
Group type: EXPERIMENTAL
Intervention: Community mobilization meetings
Number of subjects: 6836
Study 31157368 — intervention group
Group type: COMPARATOR
Intervention: Overall HIV care continuum
Number of subjects: 6836
Study 31157368 — intervention group
Group type: COMPARATOR
Intervention: National priority for HIV testing and treatment
Number of subjects: 6836
Study 28231325 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity exercise (80% of maximal perceived exertion)
Number of subjects: 76
Study 28231325 — intervention group
Group type: COMPARATOR
Intervention: Low intensity exercise (50% of maximal perceived exertion)
Number of subjects: 76
Study 28231325 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity exercise
Number of subjects: 76
Study 28231325 — intervention group
Group type: COMPARATOR
Intervention: Low intensity exercise
Number of subjects: 76
Study 25877498 — intervention group
Group type: EXPERIMENTAL
Intervention: Brodalumab 70 mg
Number of subjects: 252
Study 25877498 — intervention group
Group type: EXPERIMENTAL
Intervention: Brodalumab 140 mg
Number of subjects: 252
Study 25877498 — intervention group
Group type: EXPERIMENTAL
Intervention: Brodalumab 210 mg
Number of subjects: 252
Study 25877498 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study 23910617 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG (400mg/kg/day for 5 consecutive days)
Number of subjects: 63
Study 23910617 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 63
Study 23910617 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG (two courses)
Number of subjects: 63
Study 23910617 — intervention group
Group type: COMPARATOR
Intervention: Placebo followed by IVIG (single course)
Number of subjects: 63
Study 21368658 — intervention group
Group type: EXPERIMENTAL
Intervention: External drainage stent
Number of subjects: 158
Study 21368658 — intervention group
Group type: COMPARATOR
Intervention: No stent
Number of subjects: 158
Study 19107974 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 seroconversion
Number of subjects: 104
Study 17156223 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP at 8 cmH(2)O
Number of subjects: 46
Study 17156223 — intervention group
Group type: COMPARATOR
Intervention: PEEP at 0, 5, or 10 cmH(2)O
Number of subjects: 46
Study 15015438 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Bushen Jianpi Recipe (BJR) and low dosage erythropoietin (EPO) - 50 IU/kg subcutaneous injection twice a week and oral intake of BJR, one dose per day for 3 months.
Number of subjects: 0
Study 15015438 — intervention group
Group type: COMPARATOR
Intervention: Erythropoietin (EPO) alone - 50 IU/kg subcutaneous injection three times a week for 3 months.
Number of subjects: 0
Study 11224632 — intervention group
Group type: EXPERIMENTAL
Intervention: Islet autotransplantation (IAT) combined with total pancreatectomy (TP)
Number of subjects: 24
Study 11224632 — intervention group
Group type: COMPARATOR
Intervention: Total pancreatectomy (TP) alone
Number of subjects: 24
Study 9395702 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractors
Number of subjects: 300
Study 9395702 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncturists/Traditional Chinese Medicine
Number of subjects: 300
Study 9395702 — intervention group
Group type: EXPERIMENTAL
Intervention: Naturopaths
Number of subjects: 300
Study 9395702 — intervention group
Group type: EXPERIMENTAL
Intervention: Reiki practitioners
Number of subjects: 300
Study 9395702 — intervention group
Group type: COMPARATOR
Intervention: Family physicians
Number of subjects: 300
Study 7933527 — intervention group
Group type: EXPERIMENTAL
Intervention: Biapenem (L-627) 6 mg/kg
Number of subjects: 36
Study 7933527 — intervention group
Group type: EXPERIMENTAL
Intervention: Biapenem (L-627) 12 mg/kg
Number of subjects: 36
Study 7933527 — intervention group
Group type: EXPERIMENTAL
Intervention: Biapenem (L-627)
Number of subjects: 36
Study 3125800 — intervention group
Group type: COMPARATOR
Intervention: Intravenous feeding (IVF) alone
Number of subjects: 14
Study 3125800 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 hour of submaximal (51% of VO2max) stationary bicycle exercise daily during IVF
Number of subjects: 14
Study 3125800 — intervention group
Group type: EXPERIMENTAL
Intervention: Submaximal exercise
Number of subjects: 14
Study 31823130 — intervention group
Group type: EXPERIMENTAL
Intervention: Dotinurad (1 mg) administered orally
Number of subjects: 3
Study 28930490 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezacaftor (100 mg every day) and ivacaftor (150 mg every 12 h)
Number of subjects: 0
Study 28625368 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 100mg/day
Number of subjects: 0
Study 28625368 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25987611 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 0
Study 25987611 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 0
Study 25987611 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24028813 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus capecitabine (n=140)
Number of subjects: 280
Study 24028813 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine alone (n=140)
Number of subjects: 280
Study 24028813 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus capecitabine
Number of subjects: 280
Study 20869774 — intervention group
Group type: EXPERIMENTAL
Intervention: Amblyopia diagnosis
Number of subjects: 6830
Study 20869774 — intervention group
Group type: EXPERIMENTAL
Intervention: Underlying causes of amblyopia
Number of subjects: 6830
Study 18214943 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (30 mg elemental Zn daily for 1 year)
Number of subjects: 26
Study 17030773 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine monotherapy
Number of subjects: 14
Study 17030773 — intervention group
Group type: COMPARATOR
Intervention: Lamotrigine in combination with valproate
Number of subjects: 14
Study 17030773 — intervention group
Group type: COMPARATOR
Intervention: Users of oral contraceptives comedicated with valproate
Number of subjects: 14
Study 14646388 — intervention group
Group type: EXPERIMENTAL
Intervention: ebastine 20 mg
Number of subjects: 18
Study 14646388 — intervention group
Group type: EXPERIMENTAL
Intervention: fexofenadine 120 mg
Number of subjects: 18
Study 14646388 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study 10966901 — intervention group
Group type: EXPERIMENTAL
Intervention: TPN enriched with glutamine dipeptides (60 micromol glutamine*kg body wt(‐1)*h(‐1))
Number of subjects: 23
Study 10966901 — intervention group
Group type: COMPARATOR
Intervention: Standard TPN solution (glutamine-free)
Number of subjects: 23
Study 9007124 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 175 mg/m2 as a 3-hour infusion followed by carboplatin at a dose based on a target area under the concentration-time curve of 6 mg x min/mL.
Number of subjects: 0
Study 9007124 — intervention group
Group type: COMPARATOR
Intervention: Immediate surgery after two courses of neoadjuvant chemotherapy for responding patients.
Number of subjects: 0
Study 9007124 — intervention group
Group type: COMPARATOR
Intervention: Two courses of neoadjuvant chemotherapy for nonresponders before surgery.
Number of subjects: 0
Study 1593361 — intervention group
Group type: EXPERIMENTAL
Intervention: Loracarbef
Number of subjects: 284
Study 1593361 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin-clavulanate
Number of subjects: 284
Study 6376714 — intervention group
Group type: EXPERIMENTAL
Intervention: Endarterectomy
Number of subjects: 0
Study 6376714 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31608900 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft tissue manipulation techniques including post-isometric muscle relaxation, myofascial relaxation, and Swedish massage limited to the cervicothoracic complex
Number of subjects: 90
Study 31608900 — intervention group
Group type: COMPARATOR
Intervention: Jacobson's progressive relaxation
Number of subjects: 90
Study 29061183 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO) group (FG) supplemented with 2 g/day of FO concentrate containing 1.8 g of n-3 fatty acids for 30 days
Number of subjects: 0
Study 29061183 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (PG) received 2 g/day of mineral oil
Number of subjects: 0
Study 26428314 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem Management Plus (PM+)
Number of subjects: 346
Study 26428314 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 346
Study 23368724 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 0
Study 23368724 — intervention group
Group type: COMPARATOR
Intervention: No-touch intervention
Number of subjects: 0
Study 23368724 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 21263414 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of proton pump inhibitors (PPIs)
Number of subjects: 69
Study 21263414 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen (40 mg bolus twice a day for 3 days) of proton pump inhibitors (PPIs)
Number of subjects: 69
Study 21263414 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen of PPIs
Number of subjects: 69
Study 21263414 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of PPIs
Number of subjects: 69
Study 19656244 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic navigation system (RNS)
Number of subjects: 390
Study 19656244 — intervention group
Group type: COMPARATOR
Intervention: Manual ablation
Number of subjects: 390
Study 17366253 — intervention group
Group type: EXPERIMENTAL
Intervention: Prize-based incentives plus treatment as usual (TAU)
Number of subjects: 0
Study 17366253 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) alone
Number of subjects: 0
Study 15545559 — intervention group
Group type: EXPERIMENTAL
Intervention: Crosseal fibrin sealant
Number of subjects: 121
Study 15545559 — intervention group
Group type: COMPARATOR
Intervention: Standard topical hemostatic agents
Number of subjects: 121
Study 11273851 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose vitamin B-6 (1.6 mg/d) for 12 weeks
Number of subjects: 22
Study 11273851 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (400 microg/d for 6 weeks)
Number of subjects: 22
Study 9500719 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha2a 3 million units three times per week + Tenoxicam (20 mg/day) during 6 months
Number of subjects: 149
Study 9500719 — intervention group
Group type: COMPARATOR
Intervention: IFN-alpha2a 3 million units three times per week + placebo during 6 months
Number of subjects: 149
Study 9500719 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (G1 and G2)
Number of subjects: 149
Study 7850042 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehab program (n = 11) - comprehensive exercise program with balance retraining and goal-directed eye-head exercises, 45-minute sessions, three times per week for 12 weeks
Number of subjects: 23
Study 7850042 — intervention group
Group type: COMPARATOR
Intervention: Home program (n = 12) - Cooksey-Cawthorne eye-head exercises performed at home daily for 12 weeks
Number of subjects: 23
Study 3416548 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A cream (1,000 IU/g)
Number of subjects: 114
Study 3416548 — intervention group
Group type: COMPARATOR
Intervention: Control cream (without vitamin A)
Number of subjects: 114
Study 31911522 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition Clinic (TC)
Number of subjects: 110
Study 31911522 — intervention group
Group type: COMPARATOR
Intervention: Direct handover care (Control)
Number of subjects: 110
Study 31369180 — intervention group
Group type: EXPERIMENTAL
Intervention: DACC‐coated cotton acetate dressing
Number of subjects: 14
Study 31369180 — intervention group
Group type: COMPARATOR
Intervention: Combination of normal saline dressing and 2% mupirocin ointment
Number of subjects: 14
Study 31369180 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 14
Study 28972194 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with metabolic syndrome
Number of subjects: 1022
Study 28972194 — intervention group
Group type: COMPARATOR
Intervention: Participants without metabolic syndrome
Number of subjects: 1022
Study 23241065 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary recommendations (10 specific dietary recommendations); dietary score from 0 to 10 based on adherence
Number of subjects: 154
Study 23241065 — intervention group
Group type: EXPERIMENTAL
Intervention: Subscales of dietary recommendations
Number of subjects: 154
Study 23442750 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrograde light-guided laryngoscopy (RLGL)
Number of subjects: 205
Study 23442750 — intervention group
Group type: COMPARATOR
Intervention: Conventional direct laryngoscopy (DL)
Number of subjects: 205
Study 22082702 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge and Behavior (K&B) therapy
Number of subjects: 77
Study 22082702 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (Control)
Number of subjects: 77
Study 18823530 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 500
Study 18823530 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant treatment
Number of subjects: 500
Study 16942454 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearing a splint holding the ankle in maximum dorsiflexion nightly for 6 weeks
Number of subjects: 14
Study 12901447 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement (ME)
Number of subjects: 45
Study 12901447 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Advice (BA)
Number of subjects: 45
Study 12901447 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 45
Study 10680808 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 105
Study 9310898 — intervention group
Group type: EXPERIMENTAL
Intervention: Suboccipital stretching technique
Number of subjects: 60
Study 9310898 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral stretching technique
Number of subjects: 60
Study 9310898 — intervention group
Group type: COMPARATOR
Intervention: Sham/placebo
Number of subjects: 60
Study 8377718 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 47
Study 8377718 — intervention group
Group type: COMPARATOR
Intervention: Diuretic (hydrochlorothiazide and triamterene)
Number of subjects: 47
Study 2854738 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH therapy
Number of subjects: 16
Study 2854738 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone therapy
Number of subjects: 16
Study 2854738 — intervention group
Group type: COMPARATOR
Intervention: ACTH or Prednisone therapy
Number of subjects: 16
Study 29483842 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body cryotherapy (WBC)
Number of subjects: 0
Study 29483842 — intervention group
Group type: COMPARATOR
Intervention: Kinesiotherapy (KT)
Number of subjects: 0
Study 27561415 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D and calcium supplementation along with usual care (n=25)
Number of subjects: 53
Study 27561415 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone (n=28)
Number of subjects: 53
Study 24328847 — intervention group
Group type: EXPERIMENTAL
Intervention: A compound gel containing four amino acids and sodium hyaluronate (Aminogam(®), Errekappa, Italy)
Number of subjects: 49
Study 24328847 — intervention group
Group type: COMPARATOR
Intervention: No treatment involving a drug or gel (Control Group)
Number of subjects: 49
Study 22374696 — intervention group
Group type: EXPERIMENTAL
Intervention: FLT3ITD mRNA level
Number of subjects: 648
Study 19661804 — intervention group
Group type: EXPERIMENTAL
Intervention: Eritoran tetrasodium 105 mg
Number of subjects: 300
Study 19661804 — intervention group
Group type: EXPERIMENTAL
Intervention: Eritoran tetrasodium 45 mg
Number of subjects: 300
Study 19661804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 19661804 — intervention group
Group type: EXPERIMENTAL
Intervention: Eritoran tetrasodium 105 mg (high risk subgroup)
Number of subjects: 300
Study 19661804 — intervention group
Group type: EXPERIMENTAL
Intervention: Eritoran tetrasodium 105 mg (low risk subgroup)
Number of subjects: 300
Study 18382689 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild anemia (hemoglobin concentration between 10.0 and 11.9 g/dL in women and 10.0 and 12.9 g/dL in men)
Number of subjects: 170
Study 18382689 — intervention group
Group type: COMPARATOR
Intervention: Non-anemic controls
Number of subjects: 170
Study 16021544 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI (T1wSE, STIR, postcontrast T1wSE-fatsat)
Number of subjects: 24
Study 16021544 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI (T1wSE)
Number of subjects: 24
Study 16021544 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI (STIR)
Number of subjects: 24
Study 16021544 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI (postcontrast T1wSE-fatsat)
Number of subjects: 24
Study 16021544 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI in patients with low histological infiltration (5-20% of bone marrow)
Number of subjects: 24
Study 16021544 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI in patients with high histological infiltration (>20% of bone marrow)
Number of subjects: 24
Study 12771858 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term therapy with alprostadil (PGE(1))
Number of subjects: 0
Study 12771858 — intervention group
Group type: COMPARATOR
Intervention: Long-term therapy
Number of subjects: 0
Study 10608215 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg cisapride p.o.
Number of subjects: 64
Study 10608215 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 9154421 — intervention group
Group type: EXPERIMENTAL
Intervention: Predischarge interventions
Number of subjects: 0
Study 9154421 — intervention group
Group type: COMPARATOR
Intervention: Control group (no predischarge interventions)
Number of subjects: 0
Study 2210607 — intervention group
Group type: EXPERIMENTAL
Intervention: Penbutolol 40 mg/day orally
Number of subjects: 20
Study 2210607 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 7439241 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 300 mg
Number of subjects: 6
Study 7439241 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 200 mg
Number of subjects: 6
Study 7439241 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 200 mg slow-release
Number of subjects: 6
Study 7439241 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31662239 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy
Number of subjects: 85
Study 31662239 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo Aromatherapy
Number of subjects: 85
Study 31662239 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 85
Study 31662239 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo Acupressure
Number of subjects: 85
Study 31662239 — intervention group
Group type: COMPARATOR
Intervention: Control (routine care)
Number of subjects: 85
Study 31185312 — intervention group
Group type: EXPERIMENTAL
Intervention: Paravertebral block (PVB) with 10 ml ropivacaine 0.5% at each level from T12 to L1
Number of subjects: 65
Study 31185312 — intervention group
Group type: EXPERIMENTAL
Intervention: Paravertebral block (PVB)
Number of subjects: 65
Study 31185312 — intervention group
Group type: COMPARATOR
Intervention: Subarachnoid block (SAB) with 15 mg ropivacaine 0.5% at L3–L4 level
Number of subjects: 65
Study 31185312 — intervention group
Group type: COMPARATOR
Intervention: Subarachnoid block (SAB)
Number of subjects: 65
Study 28220309 — intervention group
Group type: EXPERIMENTAL
Intervention: Merocel packing (Group M)
Number of subjects: 90
Study 28220309 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone splint (Group S)
Number of subjects: 90
Study 28220309 — intervention group
Group type: EXPERIMENTAL
Intervention: Transseptal suturing (Group T)
Number of subjects: 90
Study 28220309 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis (applied to Groups M and S)
Number of subjects: 90
Study 26266436 — intervention group
Group type: EXPERIMENTAL
Intervention: Transepithelial corneal cross-linking
Number of subjects: 70
Study 26266436 — intervention group
Group type: COMPARATOR
Intervention: Epithelium-off corneal cross-linking
Number of subjects: 70
Study 24633272 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron therapy
Number of subjects: 41
Study 24633272 — intervention group
Group type: COMPARATOR
Intervention: Oral iron therapy
Number of subjects: 41
Study 21217152 — intervention group
Group type: EXPERIMENTAL
Intervention: Photoelectric alarms with lithium batteries
Number of subjects: 628
Study 21217152 — intervention group
Group type: EXPERIMENTAL
Intervention: Ionisation alarms with carbon/zinc batteries
Number of subjects: 628
Study 21217152 — intervention group
Group type: COMPARATOR
Intervention: Photoelectric alarms
Number of subjects: 628
Study 21217152 — intervention group
Group type: COMPARATOR
Intervention: Alarms with lithium batteries
Number of subjects: 628
Study 21217152 — intervention group
Group type: COMPARATOR
Intervention: Nuisance alarms
Number of subjects: 628
Study 19748665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 379
Study 19748665 — intervention group
Group type: EXPERIMENTAL
Intervention: Darusentan 50 mg
Number of subjects: 379